News & Publications

NEWS & PUBLICATIONS

Learn more about Prous Institute and our progress in drug discovery, technology, industry partnerships, collaborations and scientific articles.


SYMMETRY® − an ensemble of computational tools and methods aiming to replicate all the processes through which new drugs are discovered, developed and approved – supports several strategies to discover new drugs. Here we describe modifying the chemical structures of natural products to improve their pharmacological efficacy and ADMET profiles as well as identifying new indications....


Illustrates how new targeted therapies for type 2 diabetes can be discovered using the Prous Institute SYMMETRY® drug discovery platform. The approach has been successfully applied across other diverse therapeutic targets and disease areas, including cancer, pain and neurodegeneration. The platform aims to speed up the process of drug discovery and development, reducing time cost and attrition...


San Francisco, March 15, 2012 - Prous Institute for Biomedical Research and the FDA Center for Drug Evaluation and Research (CDER)  have found promising validation results for the predictive performance of mutagenicity models using Prous Institute's Symmetry® computational software and the FDA/NCTR Mold2 descriptor package. Prous Institute and the FDA/CDER are jointly presenting the...


San Francisco, March 14, 2012 - Prous Institute for Biomedical Research has reported encouraging statistically significant results for cross-validation and external validation of cytochrome P450 3A4 and 2D6 inhibitor models created using its BioEpisteme® predictive software. The findings are a result of an FDA-approved research collaboration and are being presented jointly with the FDA Center ...


Washington D.C., USA: Prous Institute for Biomedical Research will be jointly presenting a scientific poster with the US FDA Center for Drug Evaluation and Research (CDER) at the Annual Meeting of the Society of Toxicology in Washington D.C.. The poster is titled: “Computational Modeling for QT Prolongation: A Drug Cardiovascular Safety Endpoint of Paramount Importance”. The poster wil...

Page 3 of 5First   Previous   1  2  [3]  4  5  Next   Last